Greenwich LifeSciences (NASDAQ:GLSI) Releases Earnings Results

Greenwich LifeSciences (NASDAQ:GLSI) announced its quarterly earnings results on Tuesday. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.40), Zacks reports.

Greenwich LifeSciences Stock Performance

NASDAQ GLSI traded down $0.33 during trading on Tuesday, hitting $8.95. 169,244 shares of the company’s stock traded hands, compared to its average volume of 43,608. Greenwich LifeSciences has a 12-month low of $8.06 and a 12-month high of $18.75. The stock has a market capitalization of $117.65 million, a price-to-earnings ratio of -11.19 and a beta of 1.76. The business has a 50 day moving average of $11.14 and a 200-day moving average of $12.50.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $38.00 price objective on shares of Greenwich LifeSciences in a report on Tuesday, February 11th.

Insider Buying and Selling

In related news, CEO Snehal Patel acquired 3,600 shares of the firm’s stock in a transaction that occurred on Monday, April 7th. The shares were bought at an average cost of $9.10 per share, for a total transaction of $32,760.00. Following the completion of the transaction, the chief executive officer now owns 5,561,602 shares in the company, valued at approximately $50,610,578.20. This trade represents a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 51.67% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Greenwich LifeSciences

An institutional investor recently raised its position in Greenwich LifeSciences stock. Bank of America Corp DE grew its holdings in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 22.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,262 shares of the company’s stock after buying an additional 1,322 shares during the period. Bank of America Corp DE owned 0.06% of Greenwich LifeSciences worth $82,000 as of its most recent SEC filing. 4.16% of the stock is currently owned by institutional investors and hedge funds.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.